Ayahuasca
Phase 2Small molecule
Ayahuasca is one of 4 small molecule programs targeting Esketamine. It is currently in Phase 2.
2
Indications
6
Total Trials
4
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Seizures
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Approved
Keppra
UCBPhase 2
Ayahuasca
UUniversity of Sao Paulo
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esketamine3 trials
Treatment Resistant Depression1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ayahuasca. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Sao Paulo